Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1999 2
2001 2
2002 1
2004 3
2005 1
2006 3
2007 2
2008 3
2009 3
2011 3
2012 5
2013 1
2014 4
2015 3
2016 2
2018 1
2019 4
2020 6
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.
Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Schietinger A, et al. Among authors: brockstedt dg. Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9. Immunity. 2016. PMID: 27521269 Free PMC article.
Killed but metabolically active vaccines.
Dubensky TW Jr, Skoble J, Lauer P, Brockstedt DG. Dubensky TW Jr, et al. Among authors: brockstedt dg. Curr Opin Biotechnol. 2012 Dec;23(6):917-23. doi: 10.1016/j.copbio.2012.04.005. Epub 2012 May 18. Curr Opin Biotechnol. 2012. PMID: 22608846 Review.
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.
Bissonnette R, DuBois J, Facheris P, Del Duca E, Kim M, Correa Da Rosa J, Trujillo DL, Bose S, Pagan AD, Wustrow D, Brockstedt DG, Wong B, Kassner PD, Jankicevic J, Ho W, Cheng LE, Guttman-Yassky E. Bissonnette R, et al. Among authors: brockstedt dg. Allergy. 2024 Apr;79(4):924-936. doi: 10.1111/all.15949. Epub 2023 Nov 20. Allergy. 2024. PMID: 37984453 Clinical Trial.
A Potent and Effective Suicidal Listeria Vaccine Platform.
Hanson WG, Benanti EL, Lemmens EE, Liu W, Skoble J, Leong ML, Rae CS, Fassò M, Brockstedt DG, Chen C, Portnoy DA, Dubensky TW Jr, Lauer P. Hanson WG, et al. Among authors: brockstedt dg. Infect Immun. 2019 Jul 23;87(8):e00144-19. doi: 10.1128/IAI.00144-19. Print 2019 Aug. Infect Immun. 2019. PMID: 31235641 Free PMC article.
EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.
Jorapur A, Marshall LA, Jacobson S, Xu M, Marubayashi S, Zibinsky M, Hu DX, Robles O, Jackson JJ, Baloche V, Busson P, Wustrow D, Brockstedt DG, Talay O, Kassner PD, Cutler G. Jorapur A, et al. Among authors: brockstedt dg. PLoS Pathog. 2022 Jan 13;18(1):e1010200. doi: 10.1371/journal.ppat.1010200. eCollection 2022 Jan. PLoS Pathog. 2022. PMID: 35025968 Free PMC article.
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.
Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Lauer P, Brockstedt D, Patricia D, Wade M, Zudaire E, Bandyopadhyay N, Parasrampuria DA, Girgis S, Mason GE, Knoblauch RE, Stone N, Infante JR, Gottardis MM, Fong L. Drake CG, et al. Among authors: brockstedt d. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):219-228. doi: 10.1038/s41391-021-00402-8. Epub 2021 Jul 13. Prostate Cancer Prostatic Dis. 2022. PMID: 34257408 Free PMC article.
Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4.
Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, Hu DX, Jackson JJ, Pookot D, Sanchez J, Brovarney M, Wadsworth A, Chian D, Wustrow D, Kassner PD, Cutler G, Wong B, Brockstedt DG, Talay O. Marshall LA, et al. Among authors: brockstedt dg. J Immunother Cancer. 2020 Nov;8(2):e000764. doi: 10.1136/jitc-2020-000764. J Immunother Cancer. 2020. PMID: 33243932 Free PMC article.
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy.
Jackson JJ, Shibuya GM, Ravishankar B, Adusumilli L, Bradford D, Brockstedt DG, Bucher C, Bui M, Cho C, Colas C, Cutler G, Dukes A, Han X, Hu DX, Jacobson S, Kassner PD, Katibah GE, Ko MYM, Kolhatkar U, Leger PR, Ma A, Marshall L, Maung J, Ng AA, Okano A, Pookot D, Poon D, Ramana C, Reilly MK, Robles O, Schwarz JB, Shakhmin AA, Shunatona HP, Sreenivasan R, Tivitmahaisoon P, Xu M, Zaw T, Wustrow DJ, Zibinsky M. Jackson JJ, et al. Among authors: brockstedt dg. J Med Chem. 2022 Oct 13;65(19):12895-12924. doi: 10.1021/acs.jmedchem.2c00736. Epub 2022 Sep 20. J Med Chem. 2022. PMID: 36127295
52 results